CR10755A - Compounds and compositions as protein kinase inhibitors - Google Patents
Compounds and compositions as protein kinase inhibitorsInfo
- Publication number
- CR10755A CR10755A CR10755A CR10755A CR10755A CR 10755 A CR10755 A CR 10755A CR 10755 A CR10755 A CR 10755A CR 10755 A CR10755 A CR 10755A CR 10755 A CR10755 A CR 10755A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- compounds
- protein kinase
- kinase inhibitors
- inhibitors
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86437806P | 2006-11-03 | 2006-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10755A true CR10755A (es) | 2009-06-04 |
Family
ID=39119736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10755A CR10755A (es) | 2006-11-03 | 2009-04-29 | Compounds and compositions as protein kinase inhibitors |
Country Status (20)
Country | Link |
---|---|
US (1) | US20100048539A1 (es) |
EP (1) | EP2079729A1 (es) |
JP (1) | JP2010509349A (es) |
KR (2) | KR20120049397A (es) |
CN (1) | CN101622244A (es) |
AU (1) | AU2007317349B2 (es) |
BR (1) | BRPI0718677A2 (es) |
CA (1) | CA2668190A1 (es) |
CO (1) | CO6241115A2 (es) |
CR (1) | CR10755A (es) |
EA (1) | EA200970447A1 (es) |
EC (1) | ECSP099378A (es) |
IL (1) | IL198315A0 (es) |
MA (1) | MA30906B1 (es) |
MX (1) | MX2009004716A (es) |
NO (1) | NO20092138L (es) |
RU (1) | RU2009120882A (es) |
SM (1) | SMAP200900031A (es) |
TN (1) | TN2009000163A1 (es) |
WO (1) | WO2008058037A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1786799T1 (sl) | 2004-09-09 | 2012-12-31 | Natco Pharma Limited | Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze |
US8735415B2 (en) | 2004-09-09 | 2014-05-27 | Natco Pharma Limited | Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
AU2007271734B2 (en) | 2006-07-05 | 2012-03-29 | Certa Therapeutics Pty. Ltd. | Therapeutic compounds |
EP2152688A1 (en) * | 2007-05-04 | 2010-02-17 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
CA2689989A1 (en) * | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
JP5303557B2 (ja) | 2007-08-22 | 2013-10-02 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤である2−ヘテロアリールアミノ−ピリミジン誘導体 |
PT2190825E (pt) | 2007-08-22 | 2014-07-16 | Irm Llc | Compostos e composições de 5-(4- (haloalcoxi)fenil)pirimidina-2-amina como inibidores de cinases |
NZ590839A (en) * | 2008-08-13 | 2013-02-22 | Novartis Ag | Treatment of pulmonary arterial hypertension |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
BRPI1013366A2 (pt) * | 2009-03-06 | 2016-03-29 | Novartis Ag | uso de derivados de pirimidilaminobenzamida para o tratamento de distúrbios mediados pela quinase contendo zíper de leucina e quinase contendo motivo alfa estéril (zak). |
US9062076B2 (en) * | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
BR112012028530A2 (pt) * | 2010-05-07 | 2017-12-19 | Genentech Inc | composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno |
JP5855095B2 (ja) * | 2010-06-07 | 2016-02-09 | ノボメディックス,エルエルシーNovomedix,Llc | フラニル化合物およびその使用 |
JP2013542967A (ja) * | 2010-11-17 | 2013-11-28 | ノバルティス アーゲー | 3−(アミノアリール)−ピリジン化合物 |
WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
BR112014004319A2 (pt) * | 2011-09-01 | 2017-03-14 | Irm Llc | compostos e composições como inibidores de c-kit cinase |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
US9199981B2 (en) * | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
SG2014014369A (en) | 2011-09-01 | 2014-09-26 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
WO2014170350A1 (en) * | 2013-04-17 | 2014-10-23 | Albert Ludwigs Universität Freiburg | Compounds for use as bromodomain inhibitors |
CN103288804A (zh) * | 2013-05-24 | 2013-09-11 | 苏州明锐医药科技有限公司 | 一种尼洛替尼的制备方法 |
RU2681849C2 (ru) | 2013-06-05 | 2019-03-13 | Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ | Гетероциклические производные и их применение |
US20170000784A1 (en) * | 2013-12-08 | 2017-01-05 | Van Andel Research Institute | Autophagy Inhibitors |
PL3113772T3 (pl) * | 2014-03-07 | 2021-04-06 | Biocryst Pharmaceuticals, Inc. | Pirazole podstawiane trifluorometylem jako inhibitory ludzkiej kalikreiny osoczowej |
CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
CN106187995A (zh) * | 2015-05-05 | 2016-12-07 | 天津国际生物医药联合研究院 | 含酰胺键杂环类化合物及其制备方法和应用 |
MX2018002337A (es) * | 2015-09-04 | 2018-07-06 | Dow Agrosciences Llc | Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas. |
CA2999503A1 (en) * | 2015-09-23 | 2017-03-30 | Minerva Biotechnologies Corporation | Method of screening for agents for differentiating stem cells |
ES2949357T3 (es) * | 2016-03-09 | 2023-09-28 | Raze Therapeutics Inc | Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos |
EP3884939B1 (en) | 2016-03-09 | 2023-10-25 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
CN105974131B (zh) * | 2016-06-16 | 2017-12-26 | 武汉大学 | c‑Kit作为药物成瘾治疗靶点的应用 |
MX2019007030A (es) | 2016-12-15 | 2020-01-15 | Univ California | Composiciones y metodos para el tratamiento del cancer. |
CN110546133A (zh) | 2017-02-03 | 2019-12-06 | 塞尔塔治疗有限公司 | 抗纤维化化合物 |
JP6994715B2 (ja) * | 2017-10-04 | 2022-02-04 | 国立大学法人京都大学 | Bcr-Ablタンパク質イメージング用分子プローブ |
CN108187052B (zh) * | 2018-02-05 | 2021-06-08 | 苏州大学 | Akt抑制剂在制备治疗血小板数量减少相关疾病药物中的用途 |
US11767319B2 (en) | 2020-07-15 | 2023-09-26 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
US11629143B2 (en) | 2020-10-01 | 2023-04-18 | Vibliome Therapeutics, Llc | HipK4 inhibitors and uses thereof |
EP4247368A1 (en) | 2020-11-19 | 2023-09-27 | Third Harmonic Bio, Inc. | Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same |
CN113797345B (zh) * | 2021-10-22 | 2023-05-16 | 北京大学人民医院 | 糖皮质激素与糖酵解调节剂在制备急性移植物抗宿主病的药物中的应用 |
WO2023212612A2 (en) * | 2022-04-27 | 2023-11-02 | Qian Shawn | Certain chemical entities, compositions, and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60212836T2 (de) * | 2001-05-16 | 2007-01-25 | Gpc Biotech Ag | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GB0222514D0 (en) * | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
SI1786799T1 (sl) * | 2004-09-09 | 2012-12-31 | Natco Pharma Limited | Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze |
CA2592116A1 (en) * | 2004-12-23 | 2006-08-03 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US20070078121A1 (en) * | 2004-12-23 | 2007-04-05 | Flynn Daniel L | Enzyme modulators and treatments |
KR100674813B1 (ko) * | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
-
2007
- 2007-11-02 EP EP07844851A patent/EP2079729A1/en not_active Withdrawn
- 2007-11-02 KR KR1020127008731A patent/KR20120049397A/ko not_active Application Discontinuation
- 2007-11-02 KR KR1020097011383A patent/KR20090075889A/ko not_active Application Discontinuation
- 2007-11-02 US US12/513,498 patent/US20100048539A1/en not_active Abandoned
- 2007-11-02 CA CA002668190A patent/CA2668190A1/en not_active Abandoned
- 2007-11-02 MX MX2009004716A patent/MX2009004716A/es not_active Application Discontinuation
- 2007-11-02 RU RU2009120882/04A patent/RU2009120882A/ru not_active Application Discontinuation
- 2007-11-02 BR BRPI0718677-0A patent/BRPI0718677A2/pt not_active IP Right Cessation
- 2007-11-02 JP JP2009536405A patent/JP2010509349A/ja not_active Ceased
- 2007-11-02 WO PCT/US2007/083543 patent/WO2008058037A1/en active Application Filing
- 2007-11-02 EA EA200970447A patent/EA200970447A1/ru unknown
- 2007-11-02 CN CN200780049160A patent/CN101622244A/zh active Pending
- 2007-11-02 AU AU2007317349A patent/AU2007317349B2/en not_active Expired - Fee Related
-
2009
- 2009-04-23 IL IL198315A patent/IL198315A0/en unknown
- 2009-04-29 TN TNP2009000163A patent/TN2009000163A1/fr unknown
- 2009-04-29 CR CR10755A patent/CR10755A/es not_active Application Discontinuation
- 2009-05-04 CO CO09044589A patent/CO6241115A2/es not_active Application Discontinuation
- 2009-05-04 SM SM200900031T patent/SMAP200900031A/it unknown
- 2009-05-18 MA MA31895A patent/MA30906B1/fr unknown
- 2009-06-02 EC EC2009009378A patent/ECSP099378A/es unknown
- 2009-06-02 NO NO20092138A patent/NO20092138L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200970447A1 (ru) | 2009-10-30 |
TN2009000163A1 (en) | 2010-10-18 |
KR20120049397A (ko) | 2012-05-16 |
EP2079729A1 (en) | 2009-07-22 |
CN101622244A (zh) | 2010-01-06 |
AU2007317349A1 (en) | 2008-05-15 |
JP2010509349A (ja) | 2010-03-25 |
AU2007317349B2 (en) | 2011-10-20 |
ECSP099378A (es) | 2009-07-31 |
RU2009120882A (ru) | 2010-12-10 |
WO2008058037A1 (en) | 2008-05-15 |
MX2009004716A (es) | 2009-07-17 |
NO20092138L (no) | 2009-07-13 |
IL198315A0 (en) | 2010-02-17 |
BRPI0718677A2 (pt) | 2013-11-26 |
US20100048539A1 (en) | 2010-02-25 |
KR20090075889A (ko) | 2009-07-09 |
CO6241115A2 (es) | 2011-01-20 |
SMAP200900031A (it) | 2009-07-14 |
MA30906B1 (fr) | 2009-11-02 |
CA2668190A1 (en) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10755A (es) | Compounds and compositions as protein kinase inhibitors | |
CY2019013I2 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
CY2015043I2 (el) | Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων | |
HRP20141260T1 (en) | Compounds and compositions as protein kinase inhibitors | |
BRPI0719797A2 (pt) | compostos e composições como inibidores de proteína cinase | |
DE602007008837D1 (de) | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine | |
PL1891066T3 (pl) | Związki i kompozycje jako inhibitory kinazy białkowej | |
EP1841431A4 (en) | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | |
BRPI0911228A2 (pt) | compostos e composições como inibidores de proteínas quinase | |
DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
DK1713806T3 (da) | Forbindelser og sammensætninger som proteinkinaseinhibitorer | |
IL179613A0 (en) | Compounds and compositions as protein kinase inhibitors | |
IL182687A0 (en) | Compounds and compositions as protein kinase inhibitors | |
DK1943243T3 (da) | Kinase-inhibitorer | |
EP1765820A4 (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASES | |
IL194491A0 (en) | Thiazolyldihydroindazole derivatives as protein kinase inhibitors | |
NO20084739L (no) | Substituerte 3-cyanopyridiner som protein kinase inhibitorer | |
BRPI0719883A2 (pt) | Inibidores de quinase | |
GB0621720D0 (en) | Inhibitors of ikk- serine-threonine protein kinase | |
DE602006019301D1 (de) | Kinaseinhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |